Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

Dickson, Mark A. · 2014 · Clinical Cancer Research

Abstract

Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key regulator of the G1-S transition. In complex with cyclin D, CDK4 phosphorylates retinoblastoma protein (Rb) and drives cell-cycle progression, a process inhibited by p16. The p16-CDK4-cyclin D-Rb is aberrant in the majority of cancers and is, thus, a logical target for anticancer therapy. Previous attempts to block CDK4 with nonselective cyclin-dependent kinase (CDK) inhibitors led to toxicity and little efficacy. However, the recent development of selective CDK4 inhibitors launched the first successful efforts to target the pathway for cancer therapy. Three oral selective CDK4 inhibitors have entered clinical trials: palbociclib (PD0332991), LEE011, and LY2835219. CDK4 inhibitors have in vitro activity against a broad range of cancers and in patients have shown antitumor activity in breast cancer, lymphoma, sarcoma, and other tumors. Major efforts are under way to develop biomarkers of response, understand potential mechanisms of resistance, and develop rational combinations of CDK4 inhibitors with chemotherapy and other targeted drugs.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-1551

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Pishvaian, 2010 17–21, Synergistic anticancer activity of the CDK4/6 inhibitor PD-0332991 in combination with 5-fluorouracil-based chemotherapy in human colon cancer cells., Abstract nr, 70, 5047

Cited by

See all 259

Metadata

Authors
Dickson, M. A.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Dickson, Mark A.
Venue
Clinical Cancer Research
Published
2014-06-30
Volume
20
Issue
13
Pages
3379-3383
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2091851204
Cited by
245
References
39
Citations by year
2026: 4 · 2025: 9 · 2024: 6 · 2023: 24 · 2022: 14 · 2021: 14 · 2020: 27 · 2019: 18 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 42 · 2014: 9
FWCI
6.00
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CDK4 inhibitors, CDK4, G1/S transition, retinoblastoma protein phosphorylation, p16, cyclin D, palbociclib, ribociclib, breast cancer, lymphoma, sarcoma, treatment response biomarkers, drug resistance mechanisms, combination therapy
MeSH terms
Animals, Humans, Neoplasms, Research, Signal Transduction, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin D, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Pathways: CDK4 Inhibitors for Cancer Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1551
The paper
Dickson, M. A. (2014). Molecular Pathways: CDK4 Inhibitors for Cancer Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.